AbCellera Biologics (STU:8QQ) Other Net Income (Loss) : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Other Net Income (Loss)?

AbCellera Biologics's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

AbCellera Biologics's quarterly Other Net Income (Loss) declined from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil) but then increased from Dec. 2023 (€-0.00 Mil) to Mar. 2024 (€0.00 Mil).

AbCellera Biologics's annual Other Net Income (Loss) increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

AbCellera Biologics Other Net Income (Loss) Historical Data

The historical data trend for AbCellera Biologics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Other Net Income (Loss) Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

AbCellera Biologics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

AbCellera Biologics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (STU:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ABCL:USA

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines